Ten months after the introduction of anti-tumor products was approved for marketing, the cooperation was terminated for US$20 million

A few days ago, according to the E-pharmaceutical manager, Puma Biotechnology paid a one-time termination fee of 20 million U.

Previous public reports showed that as early as August 2018, Beihai Kangcheng signed an exclusive license agreement with Puma Bio for the development and commercialization of neratinib in mainland China, Taiwan, Hong Kong and Macau.

In the press release of the cooperation at that time, both parties were very satisfied with the cooperation.

Puma CEO Alan H.

It is understood that neratinib is an oral, irreversible, pan-ErbB receptor tyrosine kinase inhibitor that can effectively inhibit ErbB1 and ErbB2.

Since Beihai Kangcheng and Puma Biosciences reached a cooperation, the listing process of neratinib in China has indeed not disappointed the two.

In November 2019, neratinib was launched in Hong Kong, China, for the intensive adjuvant treatment of adult breast cancer patients with HER2 overexpression/amplification and early hormone receptor positive after completing trastuzumab therapy.

Only half a year later, in May 2020, neratinib was approved for marketing in mainland China for use in adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

Just as the commercialization of neratinib in mainland China was about to begin, the "marriage" between the two came to an abrupt end.

There is no more official information about the reasons for the suspension of cooperation.

This also awakens the current large-scale development of the "License-in" model by domestic pharmaceutical companies, and also accumulates some experience for Beihai Kangcheng, which mainly relies on the "License-in" model.

This innovative drug company that focuses on the development of bio-targeted innovative drugs for malignant tumors and precision treatments represented by rare diseases and other cutting-edge technology fields, in addition to Puma Bio, has also carried out license-in cooperation with many companies, including South Korea GC Pharma signed an exclusive license agreement in Greater China for the treatment of mucopolysaccharidosis type II Hunterase.

Regarding how to get rid of the "License-in" predicament, some business people told the E-pharmaceutical managers that there are often major changes in my country’s pharmaceutical environment.